BioSpace News Archive

Timber Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with several institutional accredited investors to sell in a registered direct offering 13,000,000 shares of the Company’s common stock, par value $0.001 per share, and Series 1 common warrants to purchase up to an aggregate of 13,000,000 shares of Common Stock at a purchase price of $0.10 per share and associated warrant.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced clinical data on the Company’s product candidate OMBLASTYS® (131I-omburtamab) for the treatment of CNS/leptomeningeal metastasis from neuroblastoma.

Pharus, Inc., a new diagnostics company spun out from Hsinchu, Taiwan-based Quark Biosciences, has named Philip Huang as its Chief Executive Officer.

AIkido Pharma Inc. provided an update on the $3 million share repurchase program authorized by the Company’s Board of Directors on January 21, 2022.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its board of directors has set October 26, 2022 as the record date (Record Date) for the dividend of shares of common stock of OmniAb, Inc. to be distributed to Ligand shareholders in order to effect the separation of Ligand and OmniAb into two independent, publicly traded companies.

Rubric Capital Management LP, an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group plc, issued an open letter to Mereo’s shareholders.

Viewpoint Molecular Targeting, Inc. announced that the U.S. Food and Drug Administration has granted fast track designation for the development of [212Pb]VMT-α-NET for treatment of patients with SSTR2-positive unresectable or metastatic neuroendocrine tumors.

The Pershing Square Sohn Cancer Research Alliance announced the opening of applications for the 2023 Pershing Square Sohn Prize for Young Investigators in Cancer Research.

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved the company’s retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production.

Acurable, an award-winning wearable medical devices company, today announced an €11m investment as a result of its Series A funding round.